Strong evidence indicates oxidative stress in the pathogenesis of Alzheimer's disease (AD). Amyloid b (Ab) has been implicated in both oxidative stress mechanisms and in neuronal apoptosis. Glutaredoxin-1 (GRX1) and thioredoxin-1 (TRX1) are antioxidants that can inhibit apoptosis signalregulating kinase (ASK1). We examined levels of GRX1 and TRX1 in AD brain as well as their effects on Ab neurotoxicity. We show an increase in GRX1 and a decrease in neuronal TRX1 in AD brains. Using SH-SY5Y cells, we demonstrate that Ab causes an oxidation of both GRX1 and TRX1, and nuclear export of Daxx, a protein downstream of ASK1. Ab toxicity was inhibited by insulin-like growth factor-I (IGF-I) and by overexpressing GRX1 or TRX1. Thus, Ab neurotoxicity might be mediated by oxidation of GRX1 or TRX1 and subsequent activation of the ASK1 cascade. Deregulation of GRX1 and TRX1 antioxidant systems could be important events in AD pathogenesis.
Introduction
Alzheimer's disease (AD) is characterized by several neuropathological changes, including accumulation of intracellular neurofibrillary tangles and extracellular plaques, as well as vast synaptic and neuronal loss. The main constituent of AD plaques is the 39-43 amino-acid long, amyloid b (Ab) peptide. Ab deposition has been proposed as the major pathogenic event that drives AD pathology. 1 The precise mechanisms leading to Ab neurotoxicity are not fully understood, but several evidences, from both in vitro and in vivo studies, suggest that oxidative stress plays a key role (for review, see Huang et al.
2 ) . Ab has been shown to induce apoptosis in several paradigms, 3 and signs of activation of apoptosis have been shown in both transgenic models of AD and in postmortem AD brain samples, 4, 5 supporting the idea that the progressive cell loss seen in AD involves apoptosis. Glutaredoxins (GRX) and thioredoxins (TRX) are endogenous antioxidant systems and key players in the balance of cellular redox homeostasis. Two glutaredoxin genes (GRX) have been found in mammals, GRX1 and GRX2.
6 GRX1 encodes GRX1, a protein that resides mainly in the cytoplasm although it can translocate into the nucleus upon certain stimuli. GRX2 encodes two isoforms, a mitochondrial and a nuclear GRX2. When oxidized, the GRX isoforms are regenerated by reduced glutathione (GSH). The resulting oxidized glutathione (GSSG) is in turn reduced by glutathione reductase at the expense of NADPH. These molecules form the glutaredoxin system in which GRX1 plays a prevalent role ( Figure 1a) . 6 At least two TRX isoforms have been characterized in mammals, cytosolic (TRX1) and mitochondrial (TRX2), of which TRX1 is the major redox protein. TRX is reduced by TRX reductase (TRXR) via NADPH. The TRX system is completed by a TRX peroxidase that is reduced by TRX and additionally scavenges reactive oxidative species (Figure 1b) . 6 In addition to their role in oxidative stress, GRX1 and TRX1 have been shown to regulate apoptosis through the apoptosis signal-regulating kinase-1 (ASK1) cascade. ASK1 is a mitogen-activated protein kinase kinase kinase (MAPKKK) that is bound to the reduced state of either GRX1 or TRX1. When GRX1 or TRX1 are oxidized, ASK1 is liberated and can initiate the MAPK cascade leading to activation of c-Jun N-terminal kinase (JNK) or p38, 7, 8 as well as to the translocation of death-associated protein (Daxx) from the nucleus to the cytosol. 9 The exogenous administration or overexpression of GRX1 or TRX1 is protective against apoptosis, as shown in several studies. 10, 11 Whether this is achieved through an inhibition of the ASK1 cascade or through other ASK1-independent mechanisms is not yet clear.
Recently, it was suggested that ASK1 activation is a key mechanism in Ab neurotoxicity, 12 but if this activation is GRX1/TRX1 dependent remains to be explored. The role of GRX1 and TRX1 in AD is largely unknown, but a few reports over recent years, albeit conflicting, suggest a possible involvement of these proteins in protection from AD oxidative stress. In an mRNA expression profiling study of AD hippocampal CA1 neurons, GRX1 was found to be downregulated in tangle-bearing neurons compared to normal neurons in AD brains. 13 Protein levels of TRX1 have also been found to be decreased in AD brain in areas associated with AD pathology. 11 In contrast, Asahina et al. 14 showed that, in AD brain, TRX1 staining was increased in astrocytes in the white matter, and suggested that this reflects the need for increased antioxidant protection.
The present study aims to provide insight into the role of GRX1 and TRX1 in Ab toxicity and AD. We first investigated the expression of GRX1 and TRX1 in AD brain. Then, using human neuroblastoma SH-SY5Y cells, we analyzed the effects of Ab on the redox states of GRX1 and TRX1, and on other antioxidant systems, specifically catalase and glutathione. Finally, we investigated the possible involvement of the ASK1 cascade in Ab-mediated apoptosis and the possible protective effects of GRX1 and TRX1 overexpression. The number of neurons and its staining intensity were estimated using a stereological semiquantitative approach. The results are summarized in Table 1 . We found that GRX1 expression was increased in neurons of AD brains (Table 1, Figure 2a ). In contrast, TRX1 expression was reduced (Table 1, Figure 2b ). Similar results were found in slices from hippocampal dentate gyrus (data not shown).
Results

GRX1 and TRX1 expressions in AD brain
In controls, GRX1 was localized mostly in the cytosolic compartment (Figures 2a and 3a) and was particularly visible in layer II, III and V pyramidal neurons. Generally, for control brains, cortical pyramidal neurons showed more immunoreactivity than hippocampal pyramidal cells. In AD brains, hippocampal neurons showed in general more immunoreactivity than cortical neurons. In AD brains, healthy neurons as determined according to Oppenheimer's criteria, including the central position of the nucleus and the presence of a single large conspicuous nucleolus, 15 displayed intensive GRX1 cytoplasmic positivity even in dendritic compartments (Figures 2a, 3b and d) . This was in contrast to neurons with morphological features indicating neurodegeneration Figure 1 Glutaredoxin (a) and thioredoxin (b) systems Figure 2 Expression of GRX1 and TRX1 in AD brains. (a) Immunostaining of GRX1 and (b) TRX1 in frontal cortex and hippocampal CA1 regions from one AD brain (female, 80 years old) and one control brain (female, 83 years old). GRX1 expression was increased, while TRX1 expression decreased in neurons of AD brains. In AD brains, an occasional increase in immunoreactivity was found in astrocyte-like profiles for TRX1 (asterisk) in all regions analyzed. Similar expression patterns were seen in the other brains studied (changes in the body shape, deformation and shifting of the nucleus to the periphery or disappearance of nucleolus), especially in hippocampal areas where a specific form of pyramidal cell degeneration (granulovacuolar degeneration) was visible (Figure 3e ).
TRX1 immunoreactivity was also mainly present in the cytosol, with no differences in intensity between brain regions. TRX1 was greatly decreased in AD brains compared with controls ( Figure 2b ). Additionally, we found occasional positively stained astrocyte-like profiles in AD brains (asterisk in Figure 2b ). Hematoxylin was used as a background staining (blue). As seen in Figure 2 , no differences were seen in hematoxylin staining in all the sections.
GRX1 is only expressed in neurons, while TRX1 is expressed in both neurons and glial cells. In addition, both neuronal loss and increased gliosis are characteristic features of AD brains. 16 Taking these facts in account, we further analyzed the expression of GRX1 and TRX1 in AD and control brains by immunoblotting. Indeed, we saw a decrease in neuronal synaptophysin and an increase in glial fibrillary acidic protein (GFAP) in AD brains (Figure 4) as indicators of neuronal loss and enhanced gliosis, respectively. As shown in Figure 4 , no major differences were seen in GRX1 and TRX1 immunoreactivity in homogenates from AD and control brains. These results together with those seen in immunohistochemistry (Table 1 and Figure 2 ) indicate that the reduced number of neurons present in AD brains express more GRX1. In addition, an increased number of glial cells in AD brains masks the differences seen in neuronal TRX1 when brain homogenates are analyzed.
Ab oxidizes GRX1 and TRX1 in a rapid, transient manner GRX1 and TRX1 are redox active proteins that can have several different redox states, varying from fully reduced to fully oxidized, depending on the surrounding cellular environment. To analyze the effects of Ab on GRX1 and TRX1 redox states, we exposed human SH-SY5Y cells for 1, 5 and 24 h to full-length Ab(1-42) (10 mM), the shorter Ab(25-35) (10 mM) and the reverse and non-toxic form Ab(35-25) (10 mM). Figure 5 shows the separation between the different redox states after incubation of the samples with AMS (4-acetamido- Figure 3 GRX1 immunoreactivity is increased in healthy neurons in AD. Staining of individual neurons with the anti-GRX1 antibody in hippocampus, dentate gyrus from control (a) and AD (b) brains and in CA1 region from control (c) and AD (d, e) brains. The neurons with high immunoreactivity of GRX1 in AD brains (b, d) showed a normal morphology (shape, central nucleus, single nucleolus). In contrast, signs of neurodegeneration such as displaced nucleus and granulovacuolar degeneration were found in AD brain neurons with low GRX1 expression (e). Bar ¼ 10 mm Figure 4 Immunoblotting of brain GRX1 and TRX1. Immunoblots of temporal cortex homogenates from control and AD cases using antibodies against GRX1, TRX1, the neuronal marker synaptophysin, the glial marker GFAP and actin. No differences were found in GRX1 and TRX1 expression between AD and control brain homogenates. As expected, synaptophysin levels were reduced and GFAP increased in AD reflecting neuronal loss and gliosis 
0 -disulfonate) and subsequent gel electrophoresis. As determined using reducing (dithiothreitol (DTT), 10 mM) or oxidizing (H 2 O 2 , 1 mM) conditions, the upper band is the fully reduced and the lower the fully oxidized redox state ( Figure 5 ).
As shown in Figure 5 , Ab(1-42) (10 mM) induced an early and transient oxidation of both GRX1 and TRX1, seen at 1 and 5 h, but not at 24 h. Ab(25-35) (10 mM) effects were very mild and also transient, being seen only at 5 h treatment. In contrast, the reverse peptide Ab(35-25) (10 mM) did not induce any significant effect.
Effects of Ab(1-42) on catalase and glutathione antioxidant systems
We next analyzed the effects of Ab(1-42) on two other major cellular antioxidant systems, namely catalase and glutathione by measuring catalase activity and levels of GSH. Catalase is an antioxidant enzyme involved in the degradation and detoxification of H 2 O 2 and glutathione is the main redox buffer in the cell. SH-SY5Y cells were treated for 1, 5 and 24 h with Ab(1-42) (10 mM). Ab(1-42) significantly increased catalase activity after 5 and 24 h (Figure 6a ). Ab(1-42) decreased GSH levels at 24 h with no effect at earlier time points (Figure 6b ).
Ab(1-42) induces apoptosis and Daxx translocation in SH-SY5Y cells GRX1 and TRX1 have been shown to be regulators of the apoptosis cascade mediated by ASK1. When reduced, GRX1 and TRX1 are bound to ASK1, thereby inhibiting its activity. In contrast, when they are oxidized ASK1 is free to initiate apoptosis. Ab(1-42) has been shown to induce apoptosis in several in vitro models. Since we showed that Ab(1-42) caused an early oxidation of both GRX1 and TRX1, we next analyzed the effects of Ab(1-42) on apoptosis and the possible involvement of the ASK1 apoptotic cascade in the Ab(1-42)-mediated cytotoxicity. We first studied effects on cell viability using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)-reduction assay. Ab(1-42) (10 mM) inhibited MTT reduction by approximately 30% at 2 h and by 40% at 5 and 24 h. This effect was significant with time (Po0,001; ANOVA), (see Figure 7a for comparisons at each time point). Ab(1-42) (10 mM) gave increased levels of apoptosis in a time-dependent manner (Po0.001; ANO-VA), with approximately 300 and 600% increases in monoand oligo-nucleosome levels after 5 and 24 h treatment, respectively, as compared to nontreated cells (Figure 7b ).
To investigate the involvement of the ASK1 cascade in the Ab(1-42)-induced apoptosis, we analyzed the Ab(1-42) effects on Daxx translocation from the nuclei to the cytosol.
Daxx is a downstream protein in the ASK1 cascade. Activation of ASK1 induces Daxx phosphorylation and its translocation to the cytosolic compartment by a JNKmediated mechanism.
9 Figure AMS was added to the samples to separate the different redox forms. To confirm the specificity of each band, reducing (DTT; 10 mM, 2 h) and oxidizing (H 2 O 2 ; 1 mM, 2 h) treatments were used. Three independent experiments gave similar results
To ensure the loading of gels and purity of the fractions, the same membranes were stripped and reblotted for the nuclearspecific protein Lamin A (nuclear fractions and cytosolic fractions) and actin (cytosolic fractions) (Figure 8a and c).
Ab(1-42) effects on Daxx relocalization were further analyzed with immunocytochemistry. As shown in Figure 8d IGF-I protects against Ab toxicity in a PI3K-independent manner IGF-I has been shown to protect against Ab toxicity in several cellular paradigms. 17, 18 This protection has been shown to involve both activation of extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways. 18 IGF-I has also been shown to inhibit ASK1 activity and therefore apoptosis, by a mechanism that is independent of its effects on the PI3K antiapoptotic cascade. 17 We next analyzed the protective effects of IGF-I against Ab(1-42) toxicity when ERK or PI3K antiapoptotic pathways were inhibited. For this, we coincubated cells with IGF-I (20 nM) and Ab(1-42) (10 mM) with and without the specific inhibitors LY294002 (50 mM; for PI3K) and U0126 (5 mM; for MEK, an upstream kinase of ERK) and then analyzed cell viability using the MTT assay.
The inhibitors were used in a 30 min pretreatment and during the coincubations with Ab(1-42) and IGF-I. The efficiency of the inhibitors was previously checked by immunoblotting extracts of treated cells with anti-phosphoAkt (a downstream serine/threonine kinase that is phosphorylated by PI3K) and anti-phospho-ERK antibodies. These To analyze the putative effects of IGF-I against Ab(1-42) toxicity, we selected a 5 h treatment, since at this time point we previously showed that Ab(1-42) induces apoptosis. As shown in Figure 9b , IGF-I (20 nM) fully protected SH-SY5Y cells against Ab(1-42) toxicity (Po0.001). When PI3K was blocked by LY294002 (50 mM), IGF-I was still protective (Po0.001). However, PI3K inhibition slightly decreased the IGF-I protection (Po0.05 against both controls and IGF-I treated cells) (Figure 9b ). When ERK was blocked by U0126 (5 mM), IGF-I did not protect against Ab(1-42) toxicity (Figure 9b ). IGF-I/Ab(1-42) cotreatment with simultaneous inhibition of both PI3K and ERK was more toxic than Ab(1-42) alone (P40.01).
Overexpression of GRX1 or TRX1 protects cells from Ab toxicity
The effects of overexpression of GRX1 or TRX1 on Ab(1-42) toxicity in SH-SY5Y cells were evaluated by studying cell viability with the MTT assay. SH-SY5Y cells were transiently transfected with either GRX1, TRX1 or the empty vector as negative control. As shown in Figure 10a , GRX1 and TRX1 expression levels were significantly increased after transfection.
Then, cells were incubated with 10 mM Ab 
Discussion
Oxidative stress is believed to have an early role in AD pathology and several reports have suggested that endogenous antioxidant systems could be affected in the disease. 19, 20 The GRX1 and TRX1 endogenous antioxidant systems are key players in maintaining the cellular redox status. 6 In addition to their role as antioxidants, both GRX1 and TRX1 have been shown to regulate apoptosis. Reduced GRX1 and TRX1 are able to bind to ASK1 and inhibit the proapoptotic MAPK cascade that leads to the activation of JNK, p38 and to the cytosolic translocation of Daxx. 7, 8 It is well known that Ab triggers the production of ROS, inducing neuronal cell death (reviewed in Small et al.
3 ). Very recently Kadowaki et al. 12 demonstrated that activation of ASK1 was a key event in Ab toxicity. Despite their importance as regulators of oxidative stress and apoptosis, the role of GRX1 and TRX1 in AD is largely unknown. To provide insight of GRX1 and TRX1 in the context of AD, we addressed the roles of GRX1 and TRX1 in the mechanisms of Ab neurotoxicity and how GRX1 and TRX1 levels are affected in AD. We found that GRX1 levels were increased in some neurons in both frontal cortex and hippocampal CA1 regions of AD brains. In contrast, we found a reduction of neuronal TRX1 levels in the same regions. This is the first study showing expression levels of GRX1 in AD brain. Two previous reports studied TRX1 in AD. Lovell et al. 11 reported a general decrease of TRX1 from several regions in AD brains. This is in apparent agreement with our study, although it was made in 14 saw an increase of TRX1 levels in astrocytes in AD brains as compared to healthy controls. In contrast with our study and with the observations of others, 21 no staining in neurons was reported in this article. However, as discussed in the results section, an increased TRX1 immunoreactivity in AD glial cells would further confirm the hypothesis that differences in neuronal TRX1 are masked when brain homogenates are analyzed.
The expressions of both GRX1 and TRX1 have been reported to be induced by various types of oxidative stress (for a review, see Grant 22 ). However, a decrease in TRX1 levels has previously been shown to occur in some diseases involving oxidative conditions, such as in neurons from spontaneously hypertensive rats. 23 The fact that TRX1 also modulates a number of transcription factors 24 and stresssignaling kinases, like ASK1 25 involved in apoptosis, suggests that a decrease of TRX1 may contribute to the neurodegenerative mechanisms of AD. On the other hand, the simultaneous increase of GRX1 in neurons of AD brains may also be of importance. The fact that those neurons overexpressing GRX1 showed an apparent normal morphology suggests that they could possibly have a better protection against the neurodegenerative events occurring in AD. In accordance with this idea, a previous report has shown that in tangle-bearing hippocampal CA1 neurons, GRX1 mRNA levels were reduced six times as compared to normal neurons in AD brains.
The upregulation of GRX1 seen in AD brain could be a compensatory effect to counteract the reduction of TRX1. An inverse relation between Grx1 and Trx1 expression has been demonstrated in Escherichia coli, where Grx1 levels are increased in bacteria lacking Trx1 and vice versa. 26 In addition, a functional link between Grx and Trx expressions has also been described in yeast, where a lack of Trx causes a decrease in GSH levels, which are compensated for by an increased Grx expression. 27 A reduction of GSH levels has been previously demonstrated in AD brain, 28 suggesting the possibility of a similar mechanism.
We treated human SH-SY5Y neuroblastoma cells with different Ab species and examined the redox status of GRX1 and TRX1. Ab is a key molecule in AD pathology and has been shown to be neurotoxic by different mechanisms including the induction of oxidative stress (for a review, see Small et al.
3 ). We found that Ab(1-42) caused a strong and early oxidation of both GRX1 and TRX1 that was transient with time. The intensity and early nature of these effects were in contrast with those seen for other antioxidant systems. We showed that catalase activity was increased at 5 and 24 h and levels of GSH were decreased after 24 h in response to Ab(1-42) treatment. Our results suggest that GRX1 and TRX1 are in the first line of response against the oxidative stress caused by Ab(1-42), at least in SH-SY5Y neuroblastoma cells. As previously discussed, the reduction in GSH levels is in accordance with earlier reports from studies with AD brain 28 and also with other in vitro studies. 29 The decrease in GSH levels could further suggest that glutathione participates in the recuperation of reduced GRX1 seen at 24 h (see Figure 1) . On the other hand, the recuperation of reduced TRX1, seen at 24 h, could indicate an additional upregulation of the reducing Several reports have shown that Ab induces apoptosis in a number of different models (for a review, see Small et al.
3 ). On the other hand, both GRX1 and TRX1 have been shown to be negative regulators of ASK1, a stress-activated and apoptotic-inducing kinase. This negative regulation of apoptosis is dependent on the redox state of GRX1 and TRX1. ASK1 is bound to the reduced form of GRX1 and TRX1, but when GRX1 and TRX1 are oxidized ASK1 is free and can initiate apoptosis. 7 In view of this, we hypothesized that the strong and quick oxidation of GRX1 and TRX1 by Ab, albeit transient, could participate in the mechanism by which Ab is proapoptotic, by liberating ASK1. Indeed, we first showed that Ab(1-42) decreased cell viability and induced apoptosis in our paradigm. We then demonstrated the involvement of the ASK1 cascade by showing that Ab induced cytosolic translocation of Daxx at 2, 5 and 24 h treatment. Daxx is a downstream protein in the ASK1 pathway located in the nucleus under normal conditions. However, under oxidative stress, ASK1 activates JNK, which phosphorylates Daxx and uncovers a nuclear export signal leading to translocation of Daxx to the cytoplasmic compartment. 9 It has also been observed that Daxx is involved in the activation of ASK1. 30 In concordance with our finding that Ab induced cytosolic translocation of Daxx, Kadowaki et al. 12 showed that ASK1 is activated by Ab in PC12 cells, and that ASK1 is in fact necessary for Ab toxicity. In primary neuronal cultures derived from E14.5 ASK À/À mice, JNK activation by Ab was excluded and cell viability was almost four-fold compared to ASK þ / þ cells. Also, others have shown that ASK1 is required for oxidative stress-induced activation of JNK, a downstream kinase of ASK1, 31 and that ASK1 is critical for Ab toxicity in SH-SY5Y cells. 18 This evidence together with our results strongly suggests that activation of ASK1 is a key mechanism for Ab neurotoxicity. Furthermore, since GRX1 and TRX1 when oxidized no longer bind to ASK1 leading to its activation, it is also suggested that the strong and early oxidation of GRX1 and TRX1 by Ab could participate in this mechanism.
To further investigate this hypothesis, we next analyzed possible strategies of protection against Ab toxicity based on inhibiting ASK1 and on overexpressing GRX1 or TRX1. Previous studies have shown that IGF-I protects cells from Ab toxicity. This protection has been shown to involve both activation of ERK and PI3K signaling pathways by IGF-I. 18 In a recent work, Galvan et al. 17 demonstrated that IGF-I treatment inhibits the ASK1 activation seen in serum-starved L929 cells independently of the PI3K pathway. Others have also shown that ASK1 can be inhibited by Akt, a serine/ threonine kinase that is activated by PI3K. 32 In view of this, we analyzed the ability of IGF-I to protect against Ab(1-42) in our model when PI3K and/or ERK pathways were blocked with the specific inhibitors LY294002 and U0126, respectively. We showed that IGF-I completely protected against Ab(1-42)-induced cell death. In accordance with Galvan et al., 17 inhibition of PI3K did not have a strong effect on the IGF-I protection against Ab toxicity. IGF-I was not protective when the MEK/ERK or both PI3K/Akt and MEK/ERK pathways were inhibited. These results provide supplementary evidence that ASK1 activation is a likely important component of the mechanism of Ab toxicity and that this toxicity may be prevented by pharmacological inhibition of ASK1.
Our results from brain tissue indicate that increased levels of GRX1 could be protective. Finally, we explored the possibility that increased levels of GRX1 or TRX1 protect SH-SY5Y cells from Ab toxicity. A number of reports have shown that raised levels of GRX or TRX by exogenous recombinant administration or by overexpression protect cells against several insults.
10,33,34 Here, we showed that increasing levels of GRX1 or TRX1 by transient transfection protect against Ab(1-42) toxicity in SH-SY5Y cells. Taking these results together with those seen in AD brains, an increase of GRX1 in healthy neurons and the general decrease of TRX1, it is suggested that increased brain levels of GRX1 and TRX1 could be beneficial for counteracting Ab toxicity and possibly also the progression of AD pathogenesis.
In summary, we demonstrate that in AD brains, GRX1 levels are increased in neurons without signs of degeneration, while neuronal TRX1 levels are generally decreased. We also demonstrate that Ab(1-42) caused an early, strong and transient oxidation of both GRX1 and TRX1, and induced apoptosis by activation of the ASK1 cascade in SH-SY5Y cells. We show that pharmacological inhibition of ASK1 by IGF-I as well as overexpression of GRX1 or TRX1 protect cells against Ab(1-42) toxicity. In view of this, we propose a model (Figure 11 ) by which Ab toxicity could occur primarily by causing oxidative stress. The GRX1 and TRX1 endogenous antioxidant systems are in the first line of defense to try to maintain the cellular redox homeostasis. However, GRX1 and TRX1 oxidations cause the liberation and activation of ASK1 and subsequent initiation of apoptosis.
Our results strongly suggest that deregulation of GRX1 and TRX1 antioxidant systems could be important in the pathogenesis of AD. Moreover, strategies leading to inhibition of Figure 11 Schematic representation of the involvement of GRX1 and TRX1 on Ab(1-42) toxicity. Oxidative stress caused by Ab induces a strong early oxidation of GRX1 and TRX1. As a consequence, the inhibitory binding of GRX1 and TRX1 to ASK1 is disrupted and ASK1 is liberated and initiates an apoptosis cascade. Treatment with IGF-I or overexpression of GRX1 or TRX1 inhibits ASK1 and protects cells against the Ab toxicity ASK1 or to an increase of GRX1 or TRX1 in neurons may have therapeutic applications for the treatment of this disease.
Materials and Methods
Materials
Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) and Ab were purchased from Sigma-Aldrich (Stockholm, Sweden). Ab(1-42) was from US Peptide (Rancho Cucamonga, CA, USA) and dissolved in serum-free minimum essential medium (MEM). Before use, the Ab was incubated at 371C with sporadic shaking for 48 h. 35 Others have shown that similar preparations of Ab(1-42) contain Ab fibrils along with protofibrils and stable oligomers. 36 AMS was from Molecular Probes (Leiden, The Netherlands). Catalase, Purpald, trichloroacetic acid (TCA), okadaic acid, phenylmethylsulfonyl fluoride (PMSF), leupeptin, aprotinin, IGF-I and thiazolyl blue tetrazolium bromide (MTT-salt) were from Sigma-Aldrich (Stockholm, Sweden). Potassium periodate was purchased from Scharlau Chemie (Barcelona, Spain). LY294002 was from Calbiochem (La Jolla, CA, USA). U0126 was from Cell Signaling Technology (Beverly, MA, USA). All other chemicals were standard laboratory reagents.
Brain samples and tissue preparation
Post-mortem brain material was obtained from the Huddinge Brain Bank (Karolinska University Hospital, Sweden) with approval by the Human Ethics Committee of Karolinska University Hospital. Four definite AD brains (two males, 79 and 89 years old; two females, 76 and 80 years old) and three age-matched control (two males, 66 and 83 years old; one 85-year-old female) were used for immunohistochemistry. All brains had a post-mortem delay between 24 and 48 h. For immunoblotting, samples from temporal cortex from six AD brains (two males and four females, 8479 years old) and four controls (four males, 6677 years old) were used. The brains had a post-mortem delay between 8 and 34 h. The AD cases met the clinical diagnosis of probable AD (Diagnostic and Statistical Manual of Mental Disorders-IV, DSM-IV criteria) as well as definite AD after Consortium to establish a Registry for Alzheimer's disease (CERAD) neuropathological criteria. 37 Brain samples intended for immunocytochemistry were fixed in buffered 4% formaldehyde and embedded in paraffin. For immunoblotting, brain samples were sonicated 4 Â 15 s in a buffer consisting of 40 mM Tris-HCl (pH 6.8) and 2% SDS, with freshly added protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA) at a dilution of 1 : 500 and phosphatase inhibitors (20 mM b-glycerophosphate, 2 nM okadaic acid, 50 mM sodium flouride, 1 mM sodium orthovanadate).
Immunohistochemical analysis
Sections (7 mm thick) were mounted onto Superfrost plus-glass (Menzel Braunschweig, Germany), baked at 371C overnight, dewaxed and hydrated. Then, sections were blocked for nonspecific sites with Dakoprotein block (X0909) (Dako, Cytomation, Denmark) for 30 min prior to incubations over night at 41C with primary antibodies (anti-GRX1 or anti-TRX1). Then, sections were incubated for 30 min with secondary antibody diluted in TBS, followed by incubation in ABC-Elite HRP (Vector laboratories Burlingame, UK) for 1 h. Reactions were visualized by developing the sections in Dab (Sigma-Aldrich, Sweden). The sections were thoroughly washed in TBS between different steps. Finally, the sections were dehydrated and mounted in DPX (BDH, Poole, UK). The protocol for antibodies was repeated to assure the reproducibility of results. All sections were treated simultaneously under the same conditions. For control staining, the primary antibody was omitted. For morphological recognition of the neurons, hematoxylin staining was used as a background.
Stereological semiquantification of immunohistochemistry
Stereological semiquantification was performed as previously described. 38 The regions used were dorsal frontal cortex pyramidal layer III, CA1 region of hippocampus and granular cell layer of dentate. A computer-generated counting frame was superimposed on the screen of a CAST-GRID 1.2 software program (Olympus, Denmark). Three slides per brain were examined. According to the intensity of the neuronal staining, the cells were divided in two groups: heavily stained cells and low or nonstained cells.
Cell culture
Human neuroblastoma SH-SY5Y cells were cultured in MEM with Earle's salts and L-alanine and L-glutamine, supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin at 371C in a humidified atmosphere of 5% (v/v) CO 2 /air. All cell culture supplies were purchased from Gibco Invitrogen Corporation (European division, Täby, Sweden). Before treatments, cells were washed with serum-free MEM. All treatments were used under serum-free conditions. Untreated cells were used as controls.
Redox state assessment
Cells were treated with Ab(25-35) (10 mM), Ab(35-25) (10 mM) or Ab(1-42) (10 mM) in MEM medium (pH 7.4) under serum-free conditions, for 1, 5 or 24 h. Untreated cells were used as controls. After treatment, cells were washed with ice-cold phosphate-buffered saline (PBS). To quench further disulfide exchange and preserve the post-treatment cellular oxidation state, the cells were rapidly treated with 20% (w/v) trichloroacetic acid (TCA). 39 Cells were harvested and collected by centrifugation (2000 Â g for 10 min) at þ 41C. TCA-treated pellets were washed twice with 70% acetone and resuspended in sample buffer (62.5 mM Tris-HCl pH 7.5, 2% SDS, 10% glycerol, 0.001% bromophenol blue) with freshly added protease inhibitors (50 mg/ml PMSF, 20 mg/ml leupeptin, 20 mg/ml aprotinin). In order to dissolve the TCA precipitates completely, the samples were sonicated. Samples were stored frozen at À801C prior to immunoblotting. Samples were boiled for 3 min at 951C prior to incubation with the thiol-specific probe AMS overnight at room temperature. AMS covalently modifies the reduced form of the proteins, which markedly retards electrophoretic migration of proteins in SDS-PAGE and gives an unequivocal separation of oxidized and reduced forms of the proteins. 39 Protein concentrations were determined using the bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA). Equivalent amounts of protein were separated by SDS-PAGE using 15 or 18% acrylamide gels.
Immunoblotting
Immunoblotting was performed as previously described. 35 Table 2 shows the different primary antibodies used. Some of the immunoblots were stripped using stripping buffer (62.5 mM Tris-HCl, pH 6.7, 2% SDS, 100 mM mercaptoethanol) at þ 501C for 30 min, and then reblotted.
For the experiments including IGF-I, cells were either left untreated or treated with 50 mM LY294002 and/or 5 mM U0126 for 30 min prior and during cotreatment with 10 mM Ab(1-42) and 20 nM IGF-I for 5 h. Cells were then washed with PBS, harvested, and collected by centrifugation at þ 41C (2000 Â g, 10 min). Cells were lysed with lysis buffer (20 mM TrisHCl pH 7.4, 137 mM NaCl, 2 mM EDTA, 2% NP-40, 2% Triton X-100) with freshly added protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA) at a dilution of 1 : 500 and phosphatase inhibitors (20 mM b-glycerophosphate, 2 nM okadaic acid, 50 mM sodium flouride, 1 mM sodium orthovanadate). Lysates were stored frozen at À801C.
Determination of catalase activity
Catalase activity was determined as described elsewhere. 40 Cells were grown in 6 cm 2 polystyrene plates. After treatment, the cells were washed with ice-cold PBS, harvested and collected by centrifugation at þ 41C (2000 Â g for 10 min). Pellets were suspended in 50 mM K 3 PO 4 pH 7.0, 1 mM EDTA buffer and sonicated. The cell lysates were centrifuged again at þ 41C (10 000 Â g for 15 min) and supernatants were saved and stored frozen at À801C prior to analyses. The assay utilizes the peroxidatic activity of catalase to transform methanol and H 2 O 2 into formaldehyde. The chromagen Purpald was used to visualize the formation of formaldehyde, by measuring the absorbance at 550 nm in a plate reader spectrophotometer (Molecular Devices Spectra MAX 250). The analysis was performed in 96-well plates using formaldehyde as standard (0-75 mM). Care was taken during the whole sample preparation not to overheat cell lysates, since this can inactivate catalase.
Measurement of reduced glutathione levels
A GSH detection kit (Chemicon, Temecula, CA, USA) was used according to the manufacturer's protocol to detect GSH levels. This kit uses the dye monochlorobimane (MCB) that has a high affinity for GSH. When unbound, MCB is almost nonfluorescent, whereas GSH-bound dye fluoresces blue. Fluorescence was measured by a FLUOstar Galaxy multiwell plate reader (BMG Labtechnologies GmbH, Offenburg, Germany), the excitation and emission wavelengths being 380 and 460 nm, respectively.
Cell viability and apoptosis measurements
Cell viability was assessed by a modified version of the MTT assay that depends on the reduction of the tetrazolium salt MTT to formazan by living cells. 35 Cells were cultured in 24-well plates and treated for the indicated time points with 10 mM Ab(1-42). For the experiments including IGF-I, medium was changed to serum-free MEM and the cells were either left untreated or treated with 50 mM LY294002 and/or 5 mM U0126 for 30 min prior and during cotreatment with 10 mM Ab(1-42) and 20 nM IGF-I for 5 h.
After treatment, a MTT solution (0.3 mg/ml) made in serum-free MEM without phenol red was added to the cells. After 1 h incubation at 371C, the MTT solution was aspirated and isopropanol was added to the cells. Aliquots were transferred to a 96-well plate and absorbances measured at 540 nm in a plate reader spectrophotometer (Molecular Devices Spectra MAX 250). Results were expressed as percentages of the respective value obtained for untreated cells at each time point.
Detection of apoptotic mono-and oligo-nucleosomes was performed using the Cell Death Detection ELISA PLUS kit (Roche Diagnostics Scandinavia AB, Bromma, Sweden) according to the manufacturer's instructions. The assay is based on a quantitative sandwich ELISA using mouse monoclonal antibodies directed against DNA and histones, respectively. This renders the in vitro determination of apoptosischaracteristic mono-and oligo-nucleosomes possible. The assay was performed in 96-well plates, measured spectrophotometrically at 405 nm (Molecular Devices Spectra MAX 250).
Immunocytochemistry
Cells grown on chamber slides were fixed in methanol for 30 min on ice. Nonspecific binding of antibodies was blocked by addition of 10% BSA in TBS-t for 30 min. Cells were incubated with primary antibody ( Immunofluorescence GRX1 and TRX1 in Alzheimer's disease S Akterin et al diluted in TBS-t with 3% BSA. Cells were rinsed in TBS-t (3 Â 10 min) before incubation with secondary antibody in TBS-t with 3% BSA for 1 h in the dark. Finally, cells were rinsed in TBS-t (3 Â 10 min) and mounted in fluorescence mounting medium (DAKO Cytomation, Glostrup, Denmark). Nikon Eclipse E800 microscope and Nikon FDX35 camera were used when analyzing the result of the immunocytochemistry.
Subcellular fractionation
Nuclear and cytosolic fractions of cells were isolated using the nuclear and cytoplasmic extraction reagents kit NE-PER (Pierce, Rockford, IL, USA), according to the manufacturer's protocol. Protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA) was added freshly at a dilution of 1 : 500. Purity of fractions was assessed by immunoblotting with antiLamin-A antibody, a nuclear membrane protein used as specific nuclear marker. Densitometric analysis of immunoreactive bands on immunoblots was performed by multiplying the optical density and the area of the selected band, obtained through NIH Image 1.63 software.
DNA constructs and transfections
The mutagenic forward primers 5 0 -CGAATTCGCCACCATGGATTACAAG GATGACGACGATAAGGCTCAAGAGTTTGTGAAC-3 0 for GRX1 and 5 0 -CGAATTCGCCACCATGGATTACAAGGATGACGACGATAAGATGGTG AAGCAGATCGAG-3 0 for TRX1, and the reverse primers 5 0 -CGGATCCTT ACTGCAGAGCTCCAATC-3 0 for GRX1 and 5 0 -CGGATCCTTAGACTAAT TCATTAAT-3 0 for TRX1 were used to amplify the respective open reading frames (ORF) by PCR from human testis Marathon-readyt cDNA (Clontech, Heidelberg, Germany). The forward primers introduced an EcoRI site followed by a Kozac sequence preceding the Flag epitope sequence and the corresponding GRX1 or TRX1 sequences. The reverse primers introduced a BamHI site after the GRX1 or TRX1 stop codons. The amplified DNA was cloned into the EcoRI-BamHI sites of the pIRESneo expression vector (Clontech, Heidelberg, Germany) and the resulting plasmids pIRES/GRX1 and pIRES/TRX1 were transformed into E. coli TOP-10 F 0 strain. The final constructs were purified using the midi-prep kit (QIAGEN Sciences, Maryland, USA) and confirmed by DNA sequencing.
Transient transfections were performed in 12-well plates using Lipofectaminet 2000 (Gibco Invitrogen Corporation; European division, Täby, Sweden) according to the manufacturer's instructions. SH-SY5Y cells were cultured until 90% confluence in 12-well plates and transfected with 0.8 mg of DNA. Cells were incubated for 24 h before changing media for serum-free MEM with or without 10 mM Ab(1-42) and cells were treated for 24 h prior to measuring cell viability.
Statistical analyses
Analyses of differences were carried out by Student's t-test or by ANOVA followed by Fisher's PLSD post hoc test. A value of Po0.05 was considered statistically significant.
